Supplementary Data from Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs
Year: 2023
Type: supplementary-materials
Abstract: Supplemental Table 1. Baseline demographics, patient characteristics, and disease characteristics by percentage HR positivity; Supplemental Table 2. HR status concordance rates in primary vs. metastatic tumors in patients with (A) HR-positive disease (n=685), (B) low HR positivity (1%-9%, n=60), and (C) moderate/high HR positivity (10%-100%, n=550); Supplemental Table 3. First-line systemic treatment by percentage HR positivity in patients with HR-positive, HER2-positive MBC; Supplemental Table 4. First-line systemic treatment by HR status and de novo vs. recurrent disease in patients with HER2-positive MBC; Supplemental Figure 1. Distribution of patients with HR-positive, HER2-positive MBC by level of HR expression; Supplemental Figure 2. Association between baseline patient and disease characteristics and overall survival in patients with HER2-positive MBC; Supplemental Figure 3. Overall survival by HR status and age in patients with HER2-positive MBC; Supplemental Figure 4. Overall survival by HR status and race in patients with HER2-positive MBC
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361937765